Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study

被引:102
作者
Kleeberger, CA
Buechner, J
Palella, F
Detels, R
Riddler, S
Godfrey, R
Jacobson, LP
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Northwestern Univ, Sch Med, Comprehens AIDS Ctr, Chicago, IL 60611 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA
[4] Univ Pittsburgh, Pittsburgh, PA 15213 USA
关键词
antiretroviral therapy; cohort studies; HIV-1; medication adherence;
D O I
10.1097/00002030-200403050-00013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To characterize the determinants of changes in adherence to antiretroviral therapy and examine whether there are persistent lower adherers. Design: A cohort study with repeated measurements. Methods: Self-reported 100% adherence was defined as taking all doses and numbers of pills over a 4-day period as prescribed for current HIV medications. Independent predictors of changing adherence (< 100% to 100% and 100% to < 100%) were determined by logistic regression, correcting for correlated repeated measures for 597 HIV-positive men reporting the use of highly active antiretroviral therapy (HAART) between October 1998 and October 2000. Results: Of the 942 visit-pairs with initial 100% adherence, 106 (11.3%) reduced adherence to less than 100%, and 836 (88.7%) remained 100% adherent at the next 6-month visit. No recent outpatient visits, younger age, depression, less than college educated, and later in calendar time predicted decreasing adherence. Among 186 visit-pairs starting with less than 100% adherence, 133 (71.5%) improved adherence to 100% and 53 (28.5%) remained less than 100% adherent at the next Visit. The determinants of improving adherence included not being African-American, not using recreational drugs, and having had more than three HAART regimens. Lower adherence was not a random event; it was significantly correlated across visits within the individual. Conclusion: Characteristics associated with improving and lowering adherence differed and should be considered in developing interventions to enhance adherence and optimize effective therapies. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:683 / 688
页数:6
相关论文
共 30 条
[1]  
[Anonymous], 1992, J EPIDEMIOLOGY JAPAN
[2]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[3]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[4]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[5]  
Centers for Disease Control and Prevention. US HIV and AIDS cases reported through December, 1996, HIV AIDS SURV REP, V8, P1
[6]   Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments [J].
Chesney, MA ;
Ickovics, JR ;
Chambers, DB ;
Gifford, AL ;
Neidig, J ;
Zwickl, B ;
Wu, AW .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03) :255-266
[7]   FACTORS ASSOCIATED WITH PREVALENT HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION IN THE MULTICENTER AIDS COHORT STUDY [J].
CHMIEL, JS ;
DETELS, R ;
KASLOW, RA ;
VANRADEN, M ;
KINGSLEY, LA ;
BROOKMEYER, R .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1987, 126 (04) :568-577
[8]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[9]  
*DHHS HJ KAIS FAM, 2001, GUID US ANT AG HIV I
[10]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199